Results

eNauka >  Rezultati >  Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
Naziv: Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
Autori: Cho, Byoung Chul; Ahn, Myung-Ju; Kang, Jin Hyoung; Soo, Ross A.; Reungwetwattana, Thanyanan; Yang, James Chih-Hsin; Cicin, Irfan; Kim, Dong-Wan; Wu, Yi-Long; Lu, Shun;
Godina: 2023
Publikacija: Journal of Clinical Oncology
ISSN: 0732-183X Journal of Clinical Oncology Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 41 br. 26 str. 4208-4217
DOI: 10.1200/JCO.23.00515
WoS-ID: 001069556400005
Scopus-ID: 2-s2.0-85170112349
PMID: 37379502
URI: https://enauka.gov.rs/handle/123456789/933671
Projekat: The authors would like to thank all the patients who participated in this study and their families and caregivers. The authors would also like to thank the physicians and nurses who cared for the patients and the staff at the clinical sites.
Izvor metapodataka: (Preuzeto iz CrossRef-a) Zarić, Bojan
(Preuzeto iz Nasi u WoS)
M-kategorija: 
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+

129
SCOPUSTM
60
PubMed CentralTM
6
OpenCitations
126
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.